Formulation and Characterization of Nanostructured Lipid Carrier Intranasal Spray Of Cariprazine using QBD Approach

Abstract

Background newlineSchizophrenia is a complex, long-lasting mental health condition marked by newlinehallucinations, delusions, disorganised speech or behaviour, and impaired cognitive newlinefunction. Around 24 million people, or 1 in 300 persons (0.32%), globally suffer with newlineschizophrenia. newlineCariprazine hydrochloride (CPZ) is a new atypical antipsychotic used to treat newlineschizophrenia. CPZ is a BCS class II drug having low aqueous solubility (0.1159 newlinemg/L). It exhibits oral bioavailability 52%. CPZ has a moderate first-pass effect. newlineConventional dosage forms of CPZ exhibits adverse effects like insomnia, akathisia, newlinenausea, hyperprolactinemia, EPS, headache, dizziness, tremors, and gastrointestinal newlinedisturbances. Many antipsychotics are not suited for oral administration from a newlinepharmacokinetic point of view due to limited bioavailability brought on by newlinegastrointestinal enzymatic degradation, hepatic first-pass effects, and/or gastrointestinal newlineadverse effects. Additionally, due to a lack of aqueous solubility and unfavourable newlinephysical/chemical or toxicological qualities, not all medications have injectable drug newlineformulations available. Intranasal delivery of nano lipid carriers enhanced the newlinebioavailability of drug molecules by obviating their first-pass metabolism and delivers newlinethem directly to the brain. newlineObjectives newlineThe present study was an attempt to systemically deliver Cariprazine HCl, a newlineschizophrenic drug via intranasal route using nanostructured lipid carrier. newline newline